New-generation antidepressants, suicide and depressed adolescents: how should clinicians respond to changing evidence?

References

• Hammad T, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332–339
   PubMed Web of Science ®Google Scholar
• Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005; 330: 389
   PubMed Web of Science ®Google Scholar
• Hammad T. Results of the analysis of suicidality in pediatric trials of newer antidepressants. Bethesda: MD: Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. Joint Meeting of the CDER Psychopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee, 2004. [cited 25 September 2007.] Available from URL: http://www.fda.gov/ohrms/dockets/ac/ 04/transcripts/2004-4065T1.pdf and http://www.fda.gov/ohrms/ dockets/ac/04/slides/2004-4065S1.htm.
   Google Scholar
• Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14857 suicides. Acta Psychiatr Scand 2005; 111: 286–290
   PubMed Web of Science ®Google Scholar
• Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292: 338–343
   PubMed Web of Science ®Google Scholar
• Leon A, Marzuk P, Tardiff K, Bucciarelli A, Markham KP, Galea S. Paroxetine, other drugs and youth suicide in New York City, through 1998. J Clin Psychiatry ; 65 1993; 2004: 915–918
   Google Scholar
• Moskos M, Olson L, Halbern S, Keller T, Gray D. Utah youth suicide study: psychological autopsy. Suicide Life Threat Behav 2005; 35: 536–546
   PubMed Web of Science ®Google Scholar
• Søndergård L, Kvist K, Andersen P, Kessing LL. Do antidepressants precipitate youth suicide: a national pharmacoepidemiological study. Eur J Child Adolesc Psychiatr 2006; 15: 232–240
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006; 163: 1898–1904
   PubMed Web of Science ®Google Scholar
• Ludwig J, Marcotte DE. Anti-depressants, suicide, and drug regulation. J Policy Anal Manage 2005; 24: 249–272
   PubMed Web of Science ®Google Scholar
• Simon G. The antidepressant quandary – considering suicide risk when treating adolescent depression. N Engl J Med 2006; 355: 2722–2723
   PubMed Web of Science ®Google Scholar
• Hall WD, Lucke J. How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality?. Aust N Z J Psychiatry 2006; 40: 941–950
   PubMed Web of Science ®Google Scholar
• Licinio J, Wong M-L. Depression, antidepressants and suicidality: a critical re-appraisal. Nat Rev Drug Discov 2005; 4: 165–171
   PubMed Web of Science ®Google Scholar
• Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005; 330:385 [Erratum: BMJ 2006; 333:30].
   PubMed Web of Science ®Google Scholar
• Fergusson D, Doucette S, Glass CK, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330: 396
   PubMed Web of Science ®Google Scholar
• Goldney RD. Suicide and antidepressants: what is the evidence?. Aust N Z J Psychiatry 2006; 40: 381–385
   PubMed Web of Science ®Google Scholar
• Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328: 879–883
   PubMed Web of Science ®Google Scholar
• Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297: 1683–1696
   PubMed Web of Science ®Google Scholar
• Kratochvil C, Emslie G, Silva S, et al. Acute time to response in the Treatment for Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45: 1412–1418
   PubMed Web of Science ®Google Scholar
• Mosholder AD, Willy M. Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis. J Child Adolesc Psychopharmacol 2006; 16: 25–32
   PubMed Web of Science ®Google Scholar
• Kaizar EE, Greenhouse JB, Seltman H, Kelleher K. Do antidepressants cause suicidality in children? A Bayesian meta-analysis. Clin Trials 2006; 3: 73–98
   PubMed Web of Science ®Google Scholar
• Klein D. The flawed basis for FDA post-marketing safety decisions: the example of antidepressants and children. Neuropsychopharmacology 2006; 31: 689–699
   PubMed Web of Science ®Google Scholar
• Mann J, Emslie G, Baldessarini R, et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 2006; 31: 473–492
   PubMed Web of Science ®Google Scholar
• Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 2005; 46: 735–754
   PubMed Web of Science ®Google Scholar
• Moreno C, Arango C, Parellada M, Shaffer D, Bird H. Antidepressants in child and adolescent depression: where are the bugs?. Acta Psychiatr Scand 2007; 115: 184–195
   PubMed Web of Science ®Google Scholar
• Cohen D. Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned?. Psychother Psychosom 2007; 76: 5–17
   PubMed Web of Science ®Google Scholar
• Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341–1345
   PubMed Web of Science ®Google Scholar
• Hetrick S, McKenzie J, Sindahl P, Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2007; (3): CD004851.
   PubMed Web of Science ®Google Scholar
• Jaffee S, Moffitt T, Caspi A, Fombonne E, Poulton R, Martin J. Differences in early childhood risk factors for juvenile-onset and adult-onset depression. Arch Gen Psychiatry 2002; 59: 215–222
   PubMed Web of Science ®Google Scholar
• Sawyer MG, Arney FM, Baghurst PA., et al. The mental health of young people in Australia: key findings from the child and adolescent component of the national survey of mental health and well-being. Aust N Z J Psychiatry 2001; 35: 806–814
   PubMed Web of Science ®Google Scholar
• Kessler RC, Walters EE. Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey. Depress Anxiety 1998; 7: 3–14
   PubMedGoogle Scholar
• Beautrais A. Risk factors for suicide and attempted suicide among young people. Aust N Z J Psychiatry 2000; 34: 420–436
   PubMed Web of Science ®Google Scholar
• Rey JM, Sawyer MG, Clark JJ, Baghurst PA. Depression among Australian adolescents. Med J Aust 2001; 175: 19–23
   PubMed Web of Science ®Google Scholar
• Vitiello B, Zuveka SH, Norquist GS. National estimates of antidepressant medication use among U.S. children, 1997–2002. J Am Acad Child Adolesc Psychiatry 2006; 45: 271–279
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164: 1356–1363
   PubMed Web of Science ®Google Scholar
• American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 1998; 37: 63S–83S
   PubMed Web of Science ®Google Scholar
• Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995; 310: 221–224
   PubMed Web of Science ®Google Scholar
• Kaufman J, Martin A, King RA, Charney D. Are child-, adolescent-, and adult-onset depression one and the same disorder?. Biol Psychiatry 2001; 49: 980–1001
   PubMed Web of Science ®Google Scholar
• Hazell P, O'Connell D, Heathcote D, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ 1995; 310: 897–901
   PubMed Web of Science ®Google Scholar
• Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002; (2): CD002317.
   PubMedGoogle Scholar
• Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 1205–1215
   PubMed Web of Science ®Google Scholar
• Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031–1037
   PubMed Web of Science ®Google Scholar
• Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003; 290: 1033–1041
   PubMed Web of Science ®Google Scholar
• Keller M, Ryan N, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 762–772
   PubMed Web of Science ®Google Scholar
• Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004; 161: 1079–1083
   PubMed Web of Science ®Google Scholar
• Kirsch D, Antonuccio D. FDA testimony of Dr David Kirsch and Dr David Antonuccio on the efficacy of antidepressants in children. New York: Alliance for Human Research Protection, 2004 [cited 21 February 2007.] Available from URL: http://www.ahrp.org/risks/ SSRI0204/KirschAntonuccio.php.
   Google Scholar
• Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005; 331: 155–157
   PubMed Web of Science ®Google Scholar
• Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292: 807–820
   PubMed Web of Science ®Google Scholar
• Timimi S. Rethinking childhood depression. BMJ 2004; 329: 1394–1396
   PubMed Web of Science ®Google Scholar
• Raz A. Perspectives on the efficacy of antidepressants for child and adolescent depression. PLoS Med 2006; 3: e9
   PubMed Web of Science ®Google Scholar
• March JS. Authors of TADS study reply to letter raising concerns. BMJ 2005; 330: 730–731
   PubMed Web of Science ®Google Scholar
• Curry J, Rodhe P, Simons A. Predictors and moderators of acute outcome in the Treatment for Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45: 1427–1438
   PubMed Web of Science ®Google Scholar
• Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007; 335: 142
   PubMed Web of Science ®Google Scholar
• The TADS Team. The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007; 64: 1132–1144
   PubMed Web of Science ®Google Scholar
• American Academy of Child and Adolescent Psychiatry (AACAP). Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. Washington, DC: AACAP, 2007. [cited 10 October 2007.] Available from URL: http://www.aacap.org/galleries/PracticeParameters/InPress_2007_DepressiveDisorders.pdf.
   Google Scholar
• March JS, Klee BJ, Kremer CME. Treatment benefit and the risk of suicidality in multicenter, randomized, controlled trials of sertraline in children and adolescents. J Child Adolesc Psychopharmacol 2006; 16: 91–102
   PubMed Web of Science ®Google Scholar
• Geller DA, Biederman J, Stewart SE, et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003; 160: 1919–1928
   PubMed Web of Science ®Google Scholar
• Seidel L, Walkup JT. Selective serotonin reuptake inhibitor use in the treatment of the pediatric non-obsessive-compulsive disorder anxiety disorders. J Child Adolesc Psychopharmacol 2006; 16: 171–179
   PubMed Web of Science ®Google Scholar
• Pine DS, Cohen P, Gurley D, Brook J, Ma Y. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry 1998; 55: 56–64
   PubMed Web of Science ®Google Scholar
• Weissman MM, Wolk S, Goldstein RB, et al. Depressed adolescents grown up. JAMA 1999; 281: 1707–1713
   PubMed Web of Science ®Google Scholar
• Masand P, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment. N Engl J Med 1991; 324: 420
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Locke CA. Re-exposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991; 52: 491–493
   PubMed Web of Science ®Google Scholar
• Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 142: 207–210
   Google Scholar
• King R, Riddle M, Chappell P, et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 1991; 30: 179–186
   PubMed Web of Science ®Google Scholar
• Beasley CM, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303: 685–692
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services PHS, Food and Drug Administration Psychopharmacological Drugs Advisory Committee. Rockville, MD: Department of Health and Human Services PHS, Food and Drug Administration, 1991. [cited 25 September 2007.] Available from URL: http://www.fda.gov/ohrms/dockets/ ac/prozac/2443T1.pdf.
   Google Scholar
• European Medicines Agency. European Medicines Agency finalises review of antidepressants in children and adolescents. LondonUK: European Medicines Agency Press office, 2005. [cited 25 September 2007.] Available from URL: http://www.emea.eu.int/pdfs/human/press/pr/12891805en.pdf.
   Google Scholar
• Australian Adverse Drug Reactions Advisory Committee. Use of SSRI antidepressants in children and adolescents. Canberra, ACT: Department of Health and Aging Therapeutic Goods Administration, 2004. [cited 25 September 2007.] Available from URL: http://www.tga.gov.au/adr/adrac_ssri.htm.
   Google Scholar
• Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007; 334: 242
   PubMed Web of Science ®Google Scholar
• Mines D, Hill D, Yu H, Novelli H. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine and citalopram. Pharmacoepidemiol Drug Saf 2005; 14: 367–372
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Newer class of antidepressants similar in effectiveness, but side effects differ. Rockville, MD: Agency for Healthcare Research and Quality, 2007. [cited 25 September 2007.] Available from URL: http://www.ahrq.gov/news/press/pr2007/antideppr.htm.
   Google Scholar
• Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003; 72: 71–80
   PubMed Web of Science ®Google Scholar
• Breggin PR. Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): a review and analysis. Int J Risk Saf Med 2004; 16: 31–49
   Google Scholar
• Healy D. Did regulators fail over selective serotonin reuptake inhibitors?. BMJ 2006; 333: 92–95
   PubMed Web of Science ®Google Scholar
• Healy D, Herxheimer A, Menkes DB. Antidepressants and violence: problems at the interface of medicine and law. PLoS Med 2006; 3: e372
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Clinical Review. Relationship between antidepressant drugs and suicidality in adults. Rockville: Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research, 2006. [cited 25 September 2007.] Available from URL: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf.
   Google Scholar
• Friedman R, Leon A. Expanding the black box: depression, antidepressants, and the risk of suicide. N Engl J Med 2007; 356: 2343–2346
   PubMed Web of Science ®Google Scholar
• Mackay F, Dunn N, Martin R, Pearce G, Freemantle S, Mann R. Newer antidepressants: a comparison of tolerability in general practice. Br J Gen Pract 1999; 49: 892–896
   PubMed Web of Science ®Google Scholar
• Mosholder AD, Pamer CA. Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants. J Child Adolesc Psychopharmacol 2006; 16: 33–36
   PubMed Web of Science ®Google Scholar
• Findling RL, McNamara NK, Stansbrey RJ, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol 2006; 16: 131–145
   PubMed Web of Science ®Google Scholar
• Moynihan R, Cassels A. Selling sickness. Nation Books, New York, NY 2005
   Google Scholar
• Bell G. The worried well: the depression epidemic and the medicalisation of our sorrows. Q Essay 2005; 18: 1–74
   Google Scholar
• Parker G. The worried well: correspondence. Q Essay 2005; 19: 88–95
   Google Scholar
• Committee of Safety of Medicines. Selective serotonin reuptake inhibitors (SSRIs): overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents. LondonUK: Medicines and Healthcare products Regulatory Agency, 2005. [cited 26 September 2007.] Available from URL: http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_ PAGE&useSecondary=true&ssDocName=CON019494&ssTargetNodeId=221.
   Google Scholar
• Shaffer D. Depressive disorders and suicide in children and adolescents. Comprehensive textbook of psychiatry, vol II, BJ Sadock, VA Sadock. Lippincott Williams & Wilkins, Philadelphia, PA 2005; 3262–3274
   Google Scholar
• Rigioni GC: Drug utilization for selected antidepressants among children & adolescents in the US. Rockville: US Food and Drug Administration, Division of Surveillance, Research and Communication Support, 2004. [cited 26 September 2007.] Available from URL: http://www.fda.gov/ohrms/dockets/AC/04/slides/4006S1_04_ Rigoni.ppt.
   Google Scholar
• Leslie L, Newman T, Chesney P, Perrin J. The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics 2005; 116: 195–204
   PubMed Web of Science ®Google Scholar
• Pfeffer C. The FDA advisories and changes in diagnosis and treatment of depression. Am J Psychiatry 2007; 164: 843–846
   PubMed Web of Science ®Google Scholar
• Wells KB. Treatment research at the crossroads. The scientific interface of clinical trials and effectiveness research. Am J Psychiatry. 1999; 156: 5–10
   PubMed Web of Science ®Google Scholar
• Black N. Why we need observational studies to evaluate the effectiveness of health research. BMJ 1996; 312: 1215–1218
   PubMed Web of Science ®Google Scholar
• Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163: 41–47
   PubMed Web of Science ®Google Scholar
• Valuck RJ, Libby AM, Sills MR, Giese AA, Allen RR. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity adjusted retrospective cohort study. CNS Drugs 2004; 18: 1119–1132
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006; 63: 1358–1367
   PubMed Web of Science ®Google Scholar
• Mayer-Gross W, Slater E, Roth M. Clinical psychiatry. Bailliere, Tindall and Cassell, LondonUK 1960
   Google Scholar
• Wessely S, Kerwin R. Suicide risk and the SSRIs. JAMA 2004; 292: 379–381
   PubMed Web of Science ®Google Scholar
• Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenbeck R, Leslie D. Age effects on antidepressant induced manic conversion. Arch Pediatr Adolesc Med 2004; 158: 773–780
   PubMed Web of Science ®Google Scholar
• Goldney R. The prediction of suicide. The international handbook of suicide and attempted suicide, K Hawton, K. van Heeringen. Wiley and Sons, ChichesterUK 2000; 585–596
   Google Scholar
• Royal Australian and New Zealand College of Psychiatrists, Royal College of General Practitioners, and Royal Australasian College of Physicians. Clinical guidelines on the use of antidepressant medications for children and adolescents. Aust Fam Physician 2005; 34: 777–778
   PubMedGoogle Scholar
• Hodes M, Garralda E. NICE guidelines on depression in children and young people: not always following the evidence. Psychiatr Bull R Coll Psychiatr 2007; 31: 361–362
   Google Scholar
• Watanabe N, Hunot V, Omori IM, Churchill R, Furukawa TA. Psychotherapy for depression among children and adolescents: a systematic review. Acta Psychiatr Scand 2007; 116: 84–95
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Konarski JZ, Segal ZV, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry 2007; 164: 778–788
   PubMed Web of Science ®Google Scholar
• Boylan K, Romero S, Birmaher B. Psychopharmacologic treatment of pediatric major depressive disorder. Psychopharmacology 2007; 191: 27–38
   PubMed Web of Science ®Google Scholar
• Therapeutic Guidelines: Psychotropic, 5th edn. Melbourne: Therapeutic Guidelines Limited, 2003.
   Google Scholar
• Heiligenstein JH, Hoog SL, Wagner KD, et al. Fluoxetine 60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10–20 mg: a pilot study. J Child Adolesc Psychopharmacol 2006; 16: 207–217
   PubMed Web of Science ®Google Scholar
• Emslie GJ, Hughes CW, Crismon ML, Lopez M, Toprac MG, Boemer C. A feasibility study of the childhood depression medication algorithm: the Texas Children's Medication Algorithm Project (CMAP). J Am Acad Child Adolesc Psychiatry 2004; 43: 519–527
   PubMed Web of Science ®Google Scholar
• Walter G, Rey J. Has the practice and outcome of ECT among adolescents changed? Findings from a whole population study. J ECT 2003; 19: 88–92
   PubMed Web of Science ®Google Scholar
• Emslie GJ, Heiligenstein JH, Hoog SL, et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004; 43: 1397–1405
   PubMed Web of Science ®Google Scholar